MLTX Investors Alert: MoonLake Immunotherapeutics Faces Securities Fraud Lawsuit – Deadline December 15

A leading securities law firm, Bleichmar Fonti & Auld LLP, has announced that a class‑action lawsuit has been filed on behalf of investors of MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX) and certain of its senior officers for alleged violations of the U.S. federal securities laws. The complaint, filed in the U.S. District Court for the Southern District of New York (captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25‑cv‑08612), asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Investors in MoonLake common stock who suffered losses have until December 15, 2025, to seek appointment as lead plaintiff. According to the filing, MoonLake — a clinical‑stage biotechnology company developing therapies for inflammatory diseases — touted its Pipeline, including the Phase 3 “VELA” trials of sonelokimab (SLK) for hidradenitis suppurativa, as separated by its “Nanobody” structure and purportedly “higher clinical responses” compared to competitors. In reality, the complaint alleges, the clinical data did not deliver a superior benefit, raising doubts about regulatory approval and commercial viability. The claim’s turning point occurred on September 28, 2025, when MoonLake disclosed that its VELA‑2 trial failed to meet its primary endpoint. Following that announcement, MoonLake’s stock price crashed nearly 90% — from approximately $61.99 on September 26 to $6.24 on September 29. The law firm says that eligible shareholders may submit their information online, on a contingency‑fee basis, with no upfront cost or responsibility for litigation expenses. Contact details are provided for Ross Shikowitz at the firm. #MoonLakeImmuno #MLTX #SecuritiesFraud #InvestorAlert #SlimScan #GrowthStocks #CANSLIM